(Q33955684)

30 July 2017

1 reference

title

Synthetic oligonucleotides as therapeutics: the coming of age. (English)

1 reference

30 July 2017

Ma DD

1

1 reference

30 July 2017

Rede T

series ordinal

2

1 reference

30 July 2017

Naqvi NA

series ordinal

3

1 reference

30 July 2017

Cook PD

series ordinal

4

1 reference

30 July 2017

1 January 2000

1 reference

Biotechnology Annual Review

30 July 2017

1 reference

30 July 2017

5

1 reference

30 July 2017

155-196

1 reference

Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Intermediate reactions in protein biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

The role of antisense RNA in gene regulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Most short DNA molecules isolated from 3T3 cells are not nascent

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense RNA and DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloro-ethylamine and nitrogen mustard residues

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Transfer of genes to humans: early lessons and obstacles to success

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

A triploblast origin for Myxozoa?

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Oligodeoxynucleotides as antisense inhibitors of gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Enzymatic amplification of translation inhibition of rabbit beta-globin mRNA mediated by anti-messenger oligodeoxynucleotides covalently linked to intercalating agents

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Selective inhibition of the cytopathic effect of type A influenza viruses by oligodeoxynucleotides covalently linked to an intercalating agent

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Hybridization arrest of globin synthesis in rabbit reticulocyte lysates and cells by oligodeoxyribonucleoside methylphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Potent and selective inhibition of gene expression by an antisense heptanucleotide

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Comparative evaluation of seven oligonucleotide analogues as potential antisense agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Oligodeoxynucleotides containing 2'-O-modified adenosine: synthesis and effects on stability of DNA:RNA duplexes

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Oligodeoxynucleotides containing C-7 propyne analogs of 7-deaza-2'-deoxyguanosine and 7-deaza-2'-deoxyadenosine

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Investigation of the solution structure of a DNA octamer [d(GGAATTCC)]2 using two-dimensional nuclear Overhauser enhancement spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Nuclear magnetic resonance and circular dichroism studies of a duplex--single-stranded hairpin loop equilibrium for the oligodeoxyribonucleotide sequence d(CGCGATTCGCG).

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Hybridization triggered cross-linking of deoxyoligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Co-suppression of Dictyostelium discoideum myosin II heavy-chain gene expression by a sense orientation transcript

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Extracellular 'communicator RNA'.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Characterization of hybridization between synthetic oligodeoxynucleotides and RNA in living cells

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Quantitative immunocytofluorographic analysis of CD4 surface antigen expression and HIV infection of human peripheral blood monocyte/macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Intracellular oligonucleotide hybridization detected by fluorescence resonance energy transfer (FRET).

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Pharmacokinetics of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense oligonucleotides: towards clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

In vivo imaging of oligonucleotides with positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Renal uptake of an 18-mer phosphorothioate oligonucleotide

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Pharmacokinetics of antisense analogues in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Biochemical and biological effects of nonionic nucleic acid methylphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Oligodeoxynucleotide stability in subcellular extracts and culture media

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular Bio Vector (SMBV).

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

High incidence of active cytomegalovirus infection among septic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

In vitro antigene therapy targeting HPV-16 E6 and E7 in cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Involvement of the bcl-2 gene in human follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Investigations of antisense oligonucleotides targeted against bcl-2 RNAs.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Selective Inhibition of Leukemia Cell Proliferation by BCR-ABL Antisense Oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Multidrug resistance and P-glycoprotein expression in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Treatment of multidrug-resistant murine leukemia with antisense mdr1 oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense technology and prospects for therapy of viral infections and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Saphenous vein graft protection: effects of c-myc antisense

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense transforming growth factor-beta 1 in wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense inhibition of hypertension in the spontaneously hypertensive rat

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense strategies in neurobiology

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense strategies in dopamine receptor pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Plasmodium falciparum: effect of chemical structure on efficacy and specificity of antisense oligonucleotides against malaria in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Inhibition of HIV-1 replication by a high-copy-number vector expressing antisense RNA for reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Epstein-Barr viral latency and cell immortalization as targets for antisense oligomers

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Inhibition of herpes simplex virus type 2 growth by phosphorothioate oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense gene therapy for neurodegenerative disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Critical issues in the antisense inhibition of brain gene expression in vivo: experiences targetting the 5-HT1A receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Sequence-specific impairment of learning by c-jun antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Antisense c-myc inhibition of lymphoma growth

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Targeted cleavage of polynucleotides by complementary oligonucleotides covalently linked to iron-porphyrins

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Targeted photochemical modification of HIV-derived oligoribonucleotides by antisense oligodeoxynucleotides linked to porphyrins

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Photo-cross-linking of psoralen-derivatized oligonucleoside methylphosphonates to single-stranded DNA

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

The 5′ terminus of the RNA moiety of U1 small nuclear ribonucleoprotein particles is required for the splicing of messenger RNA precursors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Selection of single-stranded DNA molecules that bind and inhibit human thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Current concepts in antisense drug design

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Purine nucleosides and nucleotides stimulate proliferation of a wide range of cell types

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Regulation of gene expression with double-stranded phosphorothioate oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Progress toward the structure and therapeutic use of the hairpin ribozyme

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

Single-site enzymatic cleavage of yeast genomic DNA mediated by triple helix formation

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2800%2905035-3

7 January 2021

10.1016/S1387-2656(00)05035-3

Identifiers

DOI

1 reference

30 July 2017

1 reference